Tempus AITEM reached an important technical milestone, with its Relative Strength (RS) Rating moving into the 90-plus ...

Tempus AI TEM expects full-year 2025 revenues of $1.25 billion (up from the previous $1.24 billion guidance), which represents approximately 80% annual growth. The company also expects adjusted EBITDA ...

Tempus AI Inc. (NASDAQ:TEM) is one of the best young stocks to buy and hold for 5 years. On July 8, Tempus AI announced the ...

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) investors of ...

Last week, readers were most interested in a story about an extended collaboration between Personalis and Tempus to include colorectal cancer.

ARKK surged in 2Q25 on AI and crypto bets like Circle and Tempus, with strong returns despite outflows and high sector risk.

One of Wood's favorite AI stocks has been criticized by CNBC host Jim Cramer multiple times in 2025, including this week.

Apple's $60 billion cash pile and a rare executive shake-up reignite speculation: will the tech giant finally go on an AI ...

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 12, 2025 to file lead plaintiff applications in a ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

Personalis is extending its agreement with Tempus through November 2029. The two companies are developing a minimal residual disease test to detect breast and lung cancer and solid-tumor immunotherapy ...

Personalis and Tempus AI are adding colorectal cancer as a new indication to their existing commercialization agreement.